Zhitong Finance App News, McPharmaceutical-B (02335.HK) announced that the Phase II clinical trial (this clinical trial) of MT200605, a drug candidate developed independently by the Group to treat AIS (this clinical trial), has obtained top-line data. The data shows that the clinical trial has reached its main research endpoint, and the results are statistically significant and clinically significant.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.